

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## 117793

# Maintaining acute stroke care during the covid-19 pandemic: The Tuscany stroke network performance in 2020

Marzia Baldereschi<sup>a</sup>, Giovanni Orlandi<sup>b</sup>, Pasquale Palumbo<sup>c</sup>, Patrizia Nencini<sup>d</sup>, Giuseppe Martini<sup>e</sup>, Giovanni Linoli<sup>f</sup>, Antonio Di Carlo<sup>g</sup>, Valeria Di Fabrizio<sup>h</sup>, Claudia Szasz<sup>h</sup>, Fabrizio Gemmi<sup>h</sup>Tsn Working Group<sup>i</sup>, <sup>a</sup>Italian National Research Council, Inst. of Neuroscience, Florence, Italy, <sup>b</sup>University of Pisa, Stroke Unit, Pisa, Italy, <sup>c</sup>USL Toscana Centro Soc Neurologia - Nuovo Ospedale Santo Stefano, Department of Neurology, Prato, Italy, <sup>d</sup>AOU Careggi, Stroke Unit, Firenze, Italy, <sup>c</sup>University of Siena, Stroke Unit, Siena, Italy, <sup>f</sup>USL SUDEST, Stroke Unit, Arezzo, Italy, <sup>g</sup>Italian National Research Council, Inst. of Neuroscience, Firenze, Italy, <sup>h</sup>Agenzia Regionale Sanità, Ars, Firenze, Italy, <sup>i</sup>Servizio Sanitario, Toscana, Firenze, Italy

## Background and aims

The COVID 19 pandemic is impacting on acute ischemic stroke (AIS) care: fewer patients reach the hospital within the therapeutic time-window. We aim at describing and quantifying this impact in terms of number of stroke hospital admissions and treatments across the Tuscany Stroke Network (TSN) in 2020.

The TSN was implemented in 2015 and it is structured as three hub-and-spoke systems throughout Tuscany. We retrospectively included all AIS patients admitted and those treated in each of the 22 TSN hospitals during 2020, using the 2019 as a comparator.

#### Results

Methods

From January 1 through December 312,020, a total of 1388 treatments were administered to AIS patients, being 1536 during the same period of 2019. Compared with 2019, AIS hospital admissions in 2020 decreased by 11.7% while reperfusion treatments only by 9.5%. In particular, thrombolysis decreased by 10% but endovascular tratments increased by 11.7%. Single month as well as single hospital performances varied a lot.

## Conclusions

During 2020, secondary to stay-at-home orders and possibly patients wanting to avoid healthcare facilities, stroke volumes decreased significantly across Tuscany. In addition, many patients reached hospitals beyond thrombolysis therapeutic window and were transferred to the hub for endovascular treatment. The logistic interventions provided by the TSN counterbalanced the deleterious effects of the COVID 19 outbreak on AlS care. Our data suggest both the need and the benefit of organized stroke systems. Only a well-established hospital network can adjust its organization and logistics to quickly and effectively deal with an unexpected health problem.

doi:10.1016/j.jns.2021.117793

### 117794

Covid-19-associated Guillain-Barré syndrome in the first wave of COVID-19 pandemic in Lombardia: Increased incidence or increased seroprevalence?

Filippo Martinelli Boneschi<sup>ab</sup>, Antonio Colombo<sup>c</sup>, Nereo Bresolin<sup>a</sup>, Maria Sessa<sup>d</sup>, Mattia Pozzato<sup>e</sup>, Giampiero Grampa<sup>f</sup>, Pietro Bassi<sup>g</sup>, Eugenio Magni<sup>h</sup>, Maurizio Versino<sup>i</sup>, Carlo Ferrarese<sup>j</sup>, Davide Zarcone<sup>k</sup>, Alberto Albanese<sup>1</sup>, Giuseppe Micieli<sup>m</sup>, Carla Zanferrari<sup>n</sup>, Antonio Cagnana<sup>o</sup>, Claudio Ferrante<sup>p</sup>, Angelo Zilioli<sup>q</sup>, Davide Locatelli<sup>r</sup>, Maria Calloni<sup>c</sup>, Maria Luisa Delodovici<sup>c</sup>, Camillo Foresti<sup>d</sup>, Barbara Frigeni<sup>d</sup>, Stefania Canellag, Rubjona Xhanif, Massimo Crabbioh, Alessandro Clemenzi<sup>i</sup>, Marco Mauri<sup>i</sup>, Simone Beretta<sup>s</sup>, Isidoro La Spina<sup>k</sup>, Simona Bernasconi<sup>k</sup>, Anna Cavallini<sup>t</sup>, Michela Ranieri<sup>n</sup>, Elisabetta D'Adda<sup>o</sup>, Maria Elisa Fruguglietti<sup>o</sup>, Lorenzo Peverelli<sup>q</sup>, Edoardo Agosti<sup>r</sup>, Andrea Rigamonti<sup>u</sup>, Andrea Salmaggi<sup>u</sup>, <sup>a</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>b</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit & Ms Centre, Milan, Italy, cSNO (Società Neurologi Ospedalieri), Polo Neurologico Brianteo, Seregno (MB), Italy, <sup>d</sup>ASST Papa Giovanni XXIII, Department of Neurology, Bergamo, Italy, <sup>e</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit & MS Centre, Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>f</sup>Ospedale Sant'Anna, U.o. Neurologia, Como, Italy, <sup>g</sup>Ospedale San Giuseppe, Department of Neurology, Milan, Italy, <sup>h</sup>Fondazione Poliambulanza Istituto Ospedaliero, U.o. Neurologia, Brescia. Italy. <sup>i</sup>Università dell' Insubria, U.o. Neurologia, Ospedale Di Varese, Varese, Italy, Juniversity of Milano-Bicocca, Neurology, Ospedale San Gerardo, Monza, Italy, <sup>k</sup>Ospedale Sant'Antonio Abate, U.o. Neurologia, Gallarate, Italy, <sup>1</sup>Department of Neurology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy, N/a, N/A, Italy, <sup>m</sup>Fondazione Mondino, U.o. Neurologia, Pavia, Italy, "Ospedale di Vizzolo Predabissi, U.o. Neurologia, Vizzolo Predabissi, Italy, Ospedale Maggiore, U.o. Neurologia, Crema, Italy, Pospedale Policlinico Ponte San Pietro, Department of Neurology, Bergamo, Italy, <sup>q</sup>Ospedale Maggiore, U.o. Neurologia, Lodi, Italy, "University of Insubria, Department of Neurosurgery, Varese, Italy, <sup>s</sup>University of Milano Bicocca, Department of Medicine and Surgery, Monza, Italy, tOspedale di Legnano, U.o. Di Neurologia-stroke Unit, Legnano, Italy, <sup>u</sup>Manzoni Hospital, Neurology Unit, Lecco, Italy

# Background and aims

Several studies reported increased incidence of Guillain-Barre' Syndrome (GBS) after Zika epidemic, SARS-CoV and MERS, and more recently SARS-CoV-2 infection. We estimate incidence and describe clinical characteristics and outcome of GBS in COVID-19 patients in one of the most affected regions by COVID-19 of the world, Lombardia.